| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Wells Fargo analyst Brandon Couillard downgrades Exact Sciences (NASDAQ:EXAS) from Overweight to Equal-Weight and raises the...
William Blair analyst Andrew Brackmann downgrades Exact Sciences (NASDAQ:EXAS) from Outperform to Market Perform.
Guggenheim analyst Subbu Nambi downgrades Exact Sciences (NASDAQ:EXAS) from Buy to Neutral.
Barclays analyst Luke Sergott downgrades Exact Sciences (NASDAQ:EXAS) from Overweight to Equal-Weight and raises the price t...
Nvidia Corp. (NASDAQ:NVDA) delivered another blockbuster quarter and raised its outlook, but even that wasn't enough to lif...
Abbott will acquire Exact Sciences for $21 billion, adding Cologuard and expanding its diagnostics portfolio as analysts highli...
Abbott (NYSE:ABT) and Exact Sciences (NASDAQ:EXAS) today announced a definitive agreement for Abbott to acquire Exact Sciences,...